News | May 30, 2024
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Further strengthens BaseLaunch's global pharma industry partnerships
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
The project funding will be done through a mix of internal accruals and debts.
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Subscribe To Our Newsletter & Stay Updated
